Randomized, Open Label, Phase II Study of SAR408701 Combined with Pembrolizumab Versus Pembrolizumab Alone in Patients with CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-Squamous Non?Small-Cell Lung Cancer NSQ NSCLC

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04524689

Study #:
STUDY00146221

Start Date:
Aug 23, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04524689

View Complete Trial Details & Eligibility at ClinicalTrials.gov